Stoke reports positive interim Phase 1/2a data for STK-001 in Dravet syndrome; 55% median seizure reduction at 45mg

Stoke Therapeutics, Inc.

STK-001 up to 45mg well-tolerated; 55% median reduction in convulsive seizures with three doses of 45mg (n=6).
74% of patients (20/27) experienced reduction in seizure frequency after three doses of STK-001.
Cash of $252.2M as of Sep 30, 2022 expected to fund operations into 2025; Q3 net loss $26.1M ($0.66/share).
FDA granted Rare Pediatric Disease Designation for STK-001 in Dravet syndrome in October 2022.
Planned data updates on multiple doses of 45mg and 70mg in 2023; AES presentation Dec 2-6.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Stoke Therapeutics, Inc. reported financial results for the third quarter of 2022.

Period: the third quarter of 2022
Result: reported results

Exact text from the filing

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.

View on SEC.gov

Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.